Travere therapeutics announces voluntary pause of enrollment in the phase 3 harmony study of pegtibatinase related to commercial manufacturing scale-up

San diego, sept. 26, 2024 (globe newswire) -- travere therapeutics, inc., (nasdaq: tvtx) today announced a voluntary pause of enrollment in the phase 3 harmony study evaluating pegtibatinase for the treatment of classical homocystinuria (hcu).
TVTX Ratings Summary
TVTX Quant Ranking